S&P Futures
4,158.50 -33.00 (-0.79%) Dow Futures
33,989.00 -108.00 (-0.32%) Nasdaq Futures
12,652.50 -194.25 (-1.51%) Russell 2000 Futures
2,006.80 -1.10 (-0.05%) Crude Oil
76.18 +0.30 (+0.40%) Gold
1,926.30 -4.50 (-0.23%)
Verve Therapeutics, Inc. (VERV)
After hours:
Chart Events
Performance Outlook
| Previous Close | 22.07 |
| Open | 22.69 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1200 |
| Day's Range | 22.15 - 24.64 |
| 52 Week Range | 10.70 - 43.00 |
| Volume | |
| Avg. Volume | 943,765 |
| Market Cap | 1.479B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 2.81 |
| EPS (TTM) | 8.55 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VERV
Related Research
- Verve Therapeutics, Inc.Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).RatingFair ValueEconomic Moat2 days agoMorningstar
- Benzinga
Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics
Cantor Fitzgerald initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a price target of $21. The analyst says Verve is a true pioneer in gene editing, planning to develop base editing medicines for HeFH and the prevention of ASCVD, both prevalent diseases with large potential markets. However, the analyst sees heightened regulatory and commercial risk compared to other gene-editing/ genetic medicines companies focused on rare diseases. The analyst believes it wo
- InvestorPlace
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks
- GlobeNewswire
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30 p.m. PT in San Francisco. A live webcast will be available in the investor section of the company's websit
